Nile Therapeutics announced dosing of its first patient in a Phase 2 clinical study of its lead product, CD-NP, for the treatment of acute heart failure. This single-blind, placebo-controlled study is designed to provide additional information on the safety and tolerability of CD-NP when infused for up to 72 hours in patients with acute heart failure and mild to moderate renal insufficiency. Additional exploratory endpoints will include assessments of CD-NP’s ability to relieve symptoms of acute heart failure and its effects on biomarkers of heart failure and renal function. The study is expected to enroll approximately 30 to 40 patients in the United States, Germany and Israel and will examine up to 3 doses of CD-NP.
CD-NP is a novel rationally designed chimeric peptide being studied for treatment of heart failure patients with pre-existing renal dysfunction.
For more information (415) 875-7880 or visit www.nilethera.com.